Scientific Programme

Saturday 26 June 2010

13:00	-13:15	Opening Address (Hall B)	Abstract Nr.
13:00		to EACR 21	
		e Børresen-Dale, EACR President and Conference Chair	
13:03	•	from AACR T.E. Jacks (USA)	
13:06	•	from Susan G. Komen for the Cure [®]	
	Message	by the President of the University of Oslo O.P. Ottersen (Norway)	
13:12	Message	from the Minister of Research and Higher Education of Norway T. Aasland (Norway)	
		Mühlbock Lecture (Hall B) resen-Dale (Norway)	
13:15		s and telomerase: their roles in human health and disease E.H. Blackburn (USA)	1
Chair:	K. Vousd	Symposium: Metabolism & cell death (Svalbard) len (United Kingdom) k (United Kingdom)	
14:30	metabolis	drial tumour suppressors: a genetic and biochemical link between sm and cancer E. Gottlieb (United Kingdom)	2
15:00	Tumour s	suppression by BH3-only proteins, proapoptotic members of the Bcl-2 family A. Villunger (Austria)	3
15:30	Control o	f cancer cell metabolism by nuclear receptor-based transcriptional pathways V. Giguère (Canada)	4
16:00		mutant p53 in promoting invasion K. Vousden (United Kingdom)	5
Chair:		Symposium: Animal models (Jan Mayen 1) (United Kingdom) (Israel)	
14:30		nodels for lung cancer and mesothelioma A. Berns (The Netherlands)	6
15:00	Signalling	y via the ALK receptor tyrosine kinase – insights from the fruitfly R. Palmer (Sweden)	7
15:30		ting the tissue specific functions of tumour suppressor genes and oncogenes in vivo O.J. Sansom (United Kingdom)	о 8
16:00		the p53 pathway using Zebra fish models D. Lane (United Kingdom)	g

Chair:	D. Botste	Symposium: Cancer systems biology (Jan Mayen 2) ein (USA) esi (Norway)	Abstract Nr.
14:30		R2 and EGFR alliance in cancer: defects in system control Y. Yarden (Israel)	10
15:00	From ber	nchside to byteside: what we can learn from computational modelling W. Kolch (United Kingdom)	11
15:30	A system	ns approach to identification of therapy response subsets in breast cancer J.W. Gray (USA)	12
16:00	How gen	omics has reshaped our view of cancer D. Botstein (USA)	13
18:30	-21:00	Opening Ceremony & Opening Lecture at the Opera House	
18:30	Arrival ar	nd seating in the main hall	
18:45		e and opening remarks <i>L. Børresen-Dale (Norway)</i>	
18:50	Cultural e	event: Mariann Fjeld Olsen (Opera singer)	
18:55		note from the Norwegian Cancer Society A.L. Ryel (Norway)	
19:00		note from the Radium Hospital Foundation J.V. Johannessen (Norway)	
19:05		note from the Minister of Health A. Strøm-Erichsen (Norway)	
19:10	Cultural	event: Mariann Fjeld Olsen (Opera singer)	
19:15		cancer: a challenge for science and society	
	-	D. Lane (United Kingdom)	
		event: Mariann Fjeld Olsen (Opera singer)	
20:00	Receptio	n in the Foyer	
Sun	day 27	June 2010	
07:15	-08:00	After Sunrise: Meet the Expert (Svalbard)	
07:15	-	ncer progression T.E. Jacks (USA)	14
07:15	-08:00	After Sunrise: Meet the Expert (Jan Mayen 1)	
07:15		tem cells: current controversies R. Bjerkvig (Norway)	15
07:00	00:80	Special Session: Eurocancercoms Consensus Meeting (Jan Mayen 2)	
08:00	-08:50	Educational Lecture: Immunotherapy (Svalbard)	
08:00	patients	of objective clinical responses by immunotherapy with synthetic long peptides in with high grade HPV16-induced premalignant vulva lesions C.J.M. Melief (The Netherlands)	16

08:00	-08:50	Educational Lecture: Molecular imaging (Jan Mayen 1)	Abstract Nr.
08:00		microscopy of cancer progression, regression and resistance to therapy P. Friedl (The Netherlands)	17
08:00	-08:50	Educational Lecture: Bioinformatics (Jan Mayen 2)	
08:00		g functional genomics data and networks to understand disease : O.G. Troyanskaya (USA)	18
		Radium Hospital Foundation Lecture: Epigenetics (Hall B) pssek (Germany)	
09:00		ic therapy : P.A. Jones (USA)	19
Chair:	J. Campi	Symposium: Senescence & aging (Svalbard) isi (USA) lehofer (Germany)	
10:20		d regulation of cellular senescence : S.W. Lowe (USA)	20
10:50	Molecula	r mechanisms of cellular senescence F. d'Adda di Fagagna (Italy)	21
11:20		air and cancer : H.E. Krokan (Norway)	22
11:50	Aging an	d tumour suppression: the double-edged sword of cellular senescence J. Campisi (USA)	23
		Symposium: Noncoding RNA (Jan Mayen 1)	
		oce (USA) efer (Germany)	
10:20		us microRNAs and regulatory RNA binding proteins R. Agami (The Netherlands)	24
10:50		ing RNA production by RNA polymerase III is implicated in cancer : R.J. White (United Kingdom)	25
11:20		ving microRNA, inflammatory cytokine and p53 pathways in human cancer c.C. Harris (USA)	26
11:50	Causes a	and consequences of microRNA dysregulation in cancer C.M. Croce (USA)	27
Chair:	M.J. Biss	Symposium: Tumour microenvironment interaction (Jan Mayen 2) sell (USA) zer (USA)	
10:20	melanom	et B-induced inflammatory microenvironment promotes melanocyte survival and na susceptibility P.S. Meltzer (USA)	28
10:50	Tumour:s	stroma interactions in breast cancer and glioma C. Isacke (United Kingdom)	29
11:20	Neurobla	stoma and melanoma metastasis: regulation by the tumour microenvironment	30
11:50	The epid	ermal niche: a regulator for normal and skin tumour stem cells P. Boukamp (Germany)	31

12:45	-13:45	Young Cancer Researcher's Workshops: How to be effective in applying for fellowships (Svalbard)	Abstract Nr
12:45		for Fellowships tor: R.J. White (United Kingdom)	32
13:45	-14:35	Special Session: Norwegian Pink Ribbon Lecture (Hall B)	
13:45		analysis of inherited breast and ovarian cancer: a model for personalized medicine M.C. King (USA)	33
		Presidential Session I (Svalbard) esen-Dale (Norway)	
14:35	Norwegia	n Cancer Society Award Lecture	
Susan	G. Kome Diacylgly	ur biology on for the Cure Scholarships cerol kinase contribution to mTOR-mediated breast cancer progression P. Torres-Ayuso (Spain)	34
15:05	a new lin	e-derived fibroblasts contribute to the desmoplastic reaction in breast cancer: k between breast cancer and obesity? L. Bochet (France)	35
15:20	Do breas mammog	t cancers arise in areas of the breast that pre-diagnostically had high raphic density? S. Pinto Pereira (United Kingdom)	36
15:35	Integration BRCA1 g	n analysis between differentially expressed mRNA and miRNA induced by	37
	miR-449	zky–Meziani Bursary Award induces apoptosis while triggering a stress and DNA damage response M. Lize (Germany)	38
		Presidential Session II (Jan Mayen 1) Denmark)	
	EACR Ca monocarl fundame	and experimental ancer Researcher Award 'Highly Commended' – Targeting the lactate transporter boxylate transporter 1 constitutes a new therapeutic modality that disrupts a netabolic symbiosis in tumours P. Sonveaux (Belgium)	39
14:50	human g	ceptor inhibitors target the CD44high/ld1high glioma stem cell population in lioblastoma J. Anido (Spain)	40
15:05	NOTCH2 breast tu	in breast cancer: association of SNP rs11249433 with gene expression in ER-posimours without TP53 mutations L. Prokunina-Olsson (USA)	tive 41
15:20	chemothe	eutic sphingosine 1-phosphate antibody inhibits intratumoral hypoxia and sensitizes erapy in prostate cancer animal model O. Cuvillier (France)	to 42
15:35	model fol	receptor alpha is upregulated and metastasis inhibited in a murine breast cancer lowing treatment with the novel Wnt-5a derived-hexapeptide, Foxy-5 <i>C. Ford (Australia)</i>	43
15:50	developm	nent of diagnostic and therapeutic aptamers against enzymes crucial for tumour nent and metastasis S. Missailidis (United Kingdom)	44

14:35-16:05 Presidential Session III (Jan Mayen 2) Chair: M. Pierotti (Italy)	Abstract Nr.
Oncogenomics	
14:35 Use of somatically acquired genomic rearrangements as biomarkers in solid tumours Speaker: D. McBride (United Kingdom)	45
14:50 An integrative structural and functional approach to pancreatic cancer gene discovery Speaker: A. Shain (USA)	46
15:05 Molecular signatures of long non-coding RNAs in breast cancer patients Speaker: L. Baumbusch (Norway)	47
15:20 Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer Speaker: C. Ruiz (Switzerland)	48
Molecular Biology	
15:35 New functions for an old kinase: CK1 as a key player in p53, MDM2 and E2F-1 signalling pathways Speaker: N. MacLaine (United Kingdom)	49
15:50 Cross-signaling of activated NF-kappaB and the tumour suppressor p53	50
Speaker: G. Schneider (Germany)	30
17:05-17:55 EACR Cancer Researcher Award Lecture (Hall B)	
17:05 Interplay between apoptosis and autophagy in the control of tumour cell death Speaker: K. Ryan (United Kingdom)	51
17:55-18:45 Radium Hospital Foundation Lecture: Genetic instability (Hall B) Chair: E. Olah (Hungary)	
17:55 Early epigenetic and genetic events in breast carcinogenesis Speaker: T. Tlsty (USA)	52
Poster Session Poster Nr.	Abstract Nr.
General, Molecular and Genetic Epidemiology 001-065	53-117
Translational Research 066-145	118-197
Experimental/Molecular Therapeutics, Pharmacogenomics 146-236	198-288
Tumour Immunology 237–262	289-314

Monday 28 June 2010

07:00 p53 and cancer: a complex affair Speaker: M. Oren (Israel) 07:00-08:00 After Suprise: Most the Expert (Ian Mayon 1)	315 316
07:00-08:00 After Suprise: Most the Expert / Ian Mayon 1)	316
07:00-08:00 After Sunrise: Meet the Expert (Jan Mayen 1)	316
07:00 Functional and molecular MR for breast cancer characterization Speaker: I.S. Gribbestad (Norway)	
07:00-08:00 After Sunrise: Meet the Expert (Jan Mayen 2)	
07:00 Is epigenetics the holy grail of cancer research? Speaker: Z. Herceg (France)	317
08:00-08:50 Educational Lecture: DNA damage response & novel targets (Svalbard)	
08:00 The ATM-mediated DNA damage response: the system and the pathways Speaker: Y. Shiloh (Israel)	318
08:00-08:50 Educational Lecture: Statistical analysis (Jan Mayen 1)	
08:00 Analysis of complex datasets with descriptive and predictive models – application to biomolecular pathways Speaker: K. Sachs (USA)	319
08:00-08:50 Educational Lecture: Novel diagnostics (Jan Mayen 2)	
08:00 Elucidation of pathomechanisms in human brain tumours by molecular profiling Speaker: P. Lichter (Germany)	320
09:00-09:50 Plenary Lecture: Pezcoller-EACR Lecture (Hall B) Chair: R. Perona (Spain)	
09:00 The p53 pathway: cancer, fertility, metabolic control and the central nervous system Speaker: A. Levine (USA)	321
10:20-12:20 Symposium: Epigenetics: from DNA methylation to stem cell differentiation (Svalbard) Chair: K. Helin (Denmark)	
Chair: J. Tost (France) 10:20 Mechanisms of DNA methylation in mammals	322
Speaker: F. Fuks (Belgium)	
10:50 Human cancer epigenetics: from DNA methylation to microRNAs Speaker: M. Esteller (Spain)	323
11:20 Understanding the origins of aberrant DNA methylation in cancer Speaker: I. Stancheva (United Kingdom)	324
11:50 The role histone methyl transferases and demethylases in stem cell differentiation and cancer Speaker: K. Helin (Denmark)	325

Chair:	9-12:20 Symposium: Hypoxia & angiogenesis (Jan Mayen 1) • W.G. Kaelin, Jr (USA) • J-C. Marine (Belgium)	Abstract Nr.
10:20	Targets of "angioprevention": from inflammatory angiogenesis to hypoxia Speaker: A. Albini (Italy)	326
10:50	Hypoxia-inducible factor-2alpha regulates macrophage function in mouse models of acute and tumour inflammation Speaker: C. Simon (USA)	d 327
11:20	Tumour metabolic adaptation to hypoxic and acidic stress Speaker: J. Pouyssegur (France)	328
11:50	The von Hippel-Lindau tumour suppressor protein: oxygen sensing pathways and cancer Speaker: W.G. Kaelin, Jr (USA)	329
Chair:	7-12:20 Symposium: Signalling & cancer (Jan Mayen 2) 9 R. Toftgård (Sweden) 9 J.C. Lacal (Spain)	
10:20	BRAF and RAS signalling in human melanoma Speaker: R. Marais (United Kingdom)	330
10:50	Inhibition of tumour suppressor protein phosphatase 2A (PP2A) in cancer Speaker: J. Westermarck (Finland)	331
11:20	Dual-specificity protein phosphatases and the regulation of MAP kinase signalling Speaker: S.M. Keyse (United Kingdom)	332
11:50	Hedgehog signalling in skin and pancreatic cancer Speaker: R. Toftgård (Sweden)	333
12:45	i–13:45 Young Cancer Researcher's Workshops: Career Opportunities (Svalbare	d)
12:45	Coordinator: J. Moreira (Denmark)	334
	Coordinator: B. Reve (Norway)	335
	i–14:35 Award Lecture: Anthony Dipple Carcinogenesis Award (Hall B)	
13:45	Intricacies of BRCA1 genome integrity control and cancer suppression functions Speaker: D.M. Livingston (USA)	336
Chair:	i–16:35 Symposium: Discovery based translational research (Svalbard) G.B. Mills (USA) H. Zwierzina (Austria)	
14:35	Biomarkers in early clinical development Speaker: J. Tabernero (Spain)	337
15:05	Mutations in OXPHOS and Krebs cycle genes and tumour development Speaker: M. Sobrinho Simoes (Portugal)	338
15:35	Breast cancer genomic landscapes – a first step towards personalised cancer medicine Speaker: C. Caldas (United Kingdom)	339
16:05	Delivering on the promise of personalized medicines Speaker: G.B. Mills (USA)	340

14:35–16:35 Symposium: Maintenance of genome stability (Jan Mayen 1) Chair: Y. Shiloh (Israel) Chair: J. Rzeszowska-Wolny (Poland)	Abstract Nr.
14:35 The DNA damage response machinery as an anti-cancer barrier and determinant of treatment response Speaker: J. Bartek (Denmark)	f 341
15:05 The role of chromatin in genome instability; identification of novel therapeutic targets Speaker: J.A. Downs (United Kingdom)	s 342
15:35 Synthetic lethal approaches to cancer therapy Speaker: A. Ashworth (United Kingdom)	343
16:05 The ATM-mediated DNA damage response: back to DNA repair Speaker: Y. Shiloh (Israel)	344
14:35–16:35 Symposium: Inflammation and cancer (Jan Mayen 2) Chair: M. Karin (USA) Chair: R. Giavazzi (Italy)	
14:35 Improving cancer immunotherapy by preventing chemokine nitration Speaker: A. Viola (Italy)	345
15:05 From inflammation and regeneration to hepatocarcinogenesis Speaker: E. Galun (Israel)	346
15:35 The inflammatory tumour microenvironment: tumour-protective or tumour promoting' Speaker: K. De Visser (The Netherlands)	? 347
16:05 Control of tumour progression and metastasis by inflammatory signals Speaker: M. Karin (USA)	348
17:30-18:20 Dentist O. Aase and E. Granqvist Memorial Lecture (Hall B) Chair: M. Pierotti (Italy)	
17:30 Targeted therapy – novel anti-HER2 strategies in the therapy of breast cancer Speaker: J. Baselga (Spain)	349
Poster Session Poste	er Nr. Abstract Nr.
37	-245 350-594
Survivorship Research 246-	-256 595-605
Tuesday 29 June 2010	
07:00-08:00 After Sunrise: Meet the Expert (Svalbard)	
07:00 Evolution of genetic and gene expression networks during tumour development Speaker: A. Balmain (USA)	606
07:00-08:00 After Sunrise: Meet the Expert (Jan Mayen 1)	
07:00 Exploring chemoresistance in vivo; are we making progress Speaker: P.E. Lønning (Norway)	607
08:00-08:50 Educational Lecture: Developing targeted therapy (Svalbard)	
08:00 Systems approach to personalized molecular medicine Speaker: G.B. Mills (USA)	608

08:00	-08:50	Educational Lecture: Cell cycle (Jan Mayen 1)	Abstract Nr.
08:00	In and ou Speaker:	ut of G1 S. Mittnacht (United Kingdom)	609
08:00	-08:50	Educational Lecture: RNA editing (Jan Mayen 2)	
08:00		ting meets cancer c G. Rechavi (Israel)	610
		Award Lecture: Carcinogenesis Young Investigator's Award (Hall B)	
09:00	resistanc	ous recombination in cancer development, treatment and development of drug see T. Helleday (United Kingdom)	611
Chair:	H.L. Mos	Symposium: Migration, invasion & metastases (Svalbard) ses (USA) a (Sweden)	
10:20		sis – gene expression differences associated with site and treatment sensitivity of O. Fodstad (Norway)	612
10:50		g invasion and metastasis · M. Frame (United Kingdom)	613
11:20		sms of cell signalling in metastasis · C. Marshall (United Kingdom)	614
11:50		a regulation of the inflammatory tumour microenvironment H.L. Moses (USA)	615
Chair:	S.M. Har	Symposium: CancerOmics (Jan Mayen 1) nash (USA) at (Croatia)	
10:20		ing cancer genomes P. Stephens (United Kingdom)	616
10:50		onal opportunities from genomic and chemical biology of cancer O. Kallioniemi (Finland)	617
11:20		ebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding D. Odom (United Kingdom)	618
11:50		sed breast cancer molecular signatures S.M. Hanash (USA)	619
Chair:	P. Boffett	Symposium: Chemoprevention & molecular epidemiology (Jan Mayen ta (France) tensen (Norway)	2)
10:20	-	diet to prevent cancer recurrence F. Berrino (Italy)	620
10:50	Individua	lized prediction of prostate cancer using genetic markers H. Grönberg (Sweden)	621
11:20	Genetics	of familial cancer K. Hemminki (Germany)	622
11:50		ng biomarkers of exposure, risk and outcome in epidemiology P. Boffetta (France)	623

12:20	-13:45	Workshop: Grant opportunities (Jan Mayen 1)	Abstract Nr.
		of the Marie Curie Actions in Cancer Research E. Schermer (Belgium)	624
	Grant op	portunities C. Bordignon (Italy)	625
	– 13:45 <i>A. Albini</i>	Workshop: Women in Science: Progress and promise (Jan Mayen 2) (Italy)	
12:20	•	S.A. Eccles (United Kingdom) M. Foti (USA)	626 627
		Plenary Lecture: AICR Lecture (Hall B) s (United Kingdom)	
13:45		oenvironment and the genome in breast cancer: how tissue architecture informs <i>M.J. Bissell (USA)</i>	628
Chair:	P.G. Pelic	Symposium: Cancer stem cells (Svalbard) cci (Italy) cke (Austria)	
14:35		ecular portraits of breast cancer and their relationship to mammary stem cells C.M. Perou (USA) Sponsored by Susan G. Komen for the Cure®	629
15:05	human b	ive cloning of functionally distinct breast cancer cells by use of markers from a norn reast lineage hierarchy O.W. Petersen (Denmark)	nal 630
15:35		ct of TGF-beta on glioma initiating cells J. Seoane (Spain)	631
16:05	-	on of self-renewal in cancer stem cells P.G. Pelicci (Italy)	632
Chair:	C. Prives	Symposium: Gene expression and regulation (Jan Mayen 1) iduscript (USA) iduscript (Russian Federation)	
14:35		ribution of dysregulated ribosomal gene transcription to malignant transformation <i>R.D. Hannan (Australia)</i>	633
15:05	-	on of alternative splicing by the Ewing Sarcoma Protein (EWS) and DNA damage J. Valcárcel (Spain)	634
15:35		tion and RNA Processing: links to cancer J.L. Manley (USA)	635
16:05		sms by which the p53 tumor suppressor protein selects its target genes C. Prives (USA)	636

193-215

216-250

834-856

857-891

Joint European Pathology Society-EACR Symposium: Molecular 14:35-16:35 Abstract Nr. pathology (Jan Mayen 2) Chair: M. Van de Vijver (The Netherlands) Chair: N. Brünner (Denmark) 14:35 Integrative high throughput analysis for the identification of novel therapeutic targets in breast 637 Speaker: J. Reis-Filho (United Kingdom) 15:05 Tyrosine kinase inhibitor resistance mechanisms: molecular & histologic correlates 638 Speaker: J.A. Fletcher (USA) 15:35 Optimizing pathological diagnosis with new biological tools: examples in breast cancer 639 Speaker: C. Desmedt (Belgium) 16:05 Predicting response to therapy in breast cancer 640 Speaker: M.J. Van de Vijver (The Netherlands) 17:30-18:20 Mike Price Lecture (Hall B) Chair: J. Celis (Denmark) 17:30 Tumour metabolism: back to the future 641 Speaker: T.W. Mak (Canada) **Poster Session** Poster Nr. Abstract Nr. Molecular Biology 001-149 642-790 791-822 Oncogenomics 150-181 Systems Biology 182-192 823-833

18:20-18:45 Closing Ceremony (Hall B)

Highlights of EACR-21 & farewell message

A.L. Børresen-Dale (Norway)

Introduction to the EACR-22 Conference

J. Celis (Denmark)

Radiobiology/Radiation Oncology

Carcinogenesis

Message from the National Organising Committee Chair, Barcelona 2012

J. Seoane (Spain)